#CHORONARY MGUARD PRIME MGP4028 TRIAL#
Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. InspireMD’s common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
#CHORONARY MGUARD PRIME MGP4028 FREE#
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for Carotid Stenting by providing outstanding acute results and durable stroke free long-term outcomes.
investigational device exception (IDE) for CGuard EPS to FDA expected in mid-2019 as we begin the process of accessing the U.S. Barry continued, “We look forward to further executing on our growth strategy, which includes the expansion of our commercial footprint, both in countries where we have established distribution as well as new geographies. Combining MicroNet with drug eluting capabilities would be a key differentiating feature of our coronary stent product, MGuard Prime EPS, and any other drug eluting stent product, creating what we believe are broad potential applications in the coronary drug eluting stent market.”ĭr. These patents also strengthen and broaden our overall product and technology portfolio with the inclusion of claims covering drug eluting technologies. However, our novel MicroNet stent jacket technology acts as a safety net that prevents debris from passing through the mesh, resulting in significantly lower complication rates versus conventional stenting. “Conventional stenting in patients being treated for carotid artery disease allows for the protrusion of plaque through the stent struts and into the blood vessel in up to 65% of cases, significantly increasing the risk of stroke and other complications post-procedure.
“We are pleased that the USPTO has recognized this unique technology that we believe can revolutionize the field of vascular stenting in general, but more importantly, prevent stroke in patients with carotid artery disease,” said James Barry, PhD, Chief Executive Officer of InspireMD. The claims also cover MGuard Prime™ EPS for patients being treated for acute myocardial infarction. MicroNet is a key differentiator of InspireMD’s commercial products, including the company’s lead product, CGuard™ EPS, for the prevention of stroke in patients being treated for carotid artery disease. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patents 10,070,976 and 10,070,977 covering InspireMD’s proprietary MicroNet™ stent jacket combined with a stent scaffold and related drug eluting technologies. 17, 2018 (GLOBE NEWSWIRE) - InspireMD, Inc.
0 kommentar(er)
